Core Instructions News Today

NVNS reduces symptoms of PTSD by 31% in sham-controlled study...

GuruFocus Article or News written by GuruFocusNews and the topic is about:

ROCKAWAY, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced...

ROCKAWAY, N.J., June 02, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced...

electroCore, Inc. Announces Johns Hopkins University School of Medicine Study of Non-Invasive Vagus Nerve Stimulation (nVNS) for Symptomatic Exacerbation of Nausea in Patients with Gastroparesis and Related Disorders April 26, 2021 08:00 ET | Source: electroCore, Inc. electroCore, Inc. Rockaway, New Jersey, UNITED STATES ROCKAWAY, NJ, April 26, 2021 (GLOBE NEWSWIRE) --  -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine...

Share: Amid the vaccine roll out, 97,309 new cases of COVID-19 have been reported to the CDC. Peter Staats, M.D. Chief Medical Officer of electroCore, Inc. (NASDAQ:ECOR), outlines common COVID-19 symptoms and at-home steps that can be discussed with health care providers to reduce symptoms. At-home steps to reduce COVID-19 symptoms: Confusion and Brain Fog: Although brain fog is not a true medical condition, it is a common symptom for many COVID-19 patients. Confusion and brain fog can be very ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. electroCore Announces Publication of Study on Non-Invasive Vagus Nerve Stimulation (nVNS) to ... electroCoreFebruary 9, 2021 GMT ROCKAWAY, N.J., Feb. 09, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer reviewed paper, entitled: “Non-invasive vagus nerve stimulation to reduce ileus after major col...

Published: Feb 02, 2021 ROCKAWAY, N.J., Feb. 02, 2021 (GLOBE NEWSWIRE) -- electroCore Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that full enrollment has been achieved for the TR-VENUS study of non-invasive vagal nerve stimulation (nVNS) for the acute treatment of stroke. TR-VENUS is a double blind, randomized, sham-controlled, multi-center clinical trial, conducted at nine major medical centers across Turkey, supported by the Turkish Neurologic...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. electroCore, Inc. Announces Agreement with Pro Medical Baltic to be Exclusive Distributor for ... electroCoreDecember 21, 2020 GMT ROCKAWAY, N.J., Dec. 21, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has entered into an agreement with Pro Medical Baltic UAB (“PMB”), whereby PMB will serve as the exclusive ...

electroCore Announces Positive Top-Line Results from PREMIUM II Migraine Prevention Study December 08, 2020 08:00 ET | Source: electroCore electroCore Basking Ridge, New Jersey, UNITED STATES BASKING RIDGE, N.J., Dec. 08, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today top-line results from its GM-US-10 (PREMIUM II) study. Despite the early termination of the study in Apr...